RE:I did some deep DD/ digging….what could Onc be worth?Canadafan - once again your logic on evaluation is flawed since you have chosen to look backwards, by simply choosing the rate of inflation (3%) as an example to support your argument, rather than taking a forward looking perspective that includes what ONCY has RECENTLY discovered with the combinational use of pelareorep today, and the ability to use pelareorep in more cancer indications and with more I/O agents than before. AND then we have to look at what the value of the company is NOW WORTH, given the new M&A information that has come into focus, including the recent acquisition values of some startup and pre-clinical companies like MiroBio, and Trillium for example, AND the M&A analysis of global consulting companies like PwC who have looked at "bolt-on" acquisitions and the value of those "bolt-ons', such as Pfizer's acquisition of the single product platform company Biohaven, as an example, notwithstanding the smaller market that Biohaven's migraine drug addresses.
And this is happening at a time when Big Pharma is demonstrating serious intent on making higher valued M&A deals than in the past, in their effort to counter the effect of the fast approaching patent cliff that they will all face by 2025 and beyond.
Unfortunately your simple analysis does not take any of this into consideration, but if it did, it would better reflect why ONCY as a company is more comparatively valued towards the USD$ 8 Billion to USD$ 15 Billion range, than anything cited otherwise.